Gyre Therapeutics Inc

CEO Luo Ying’s recent Gyre Therapeutics stock sales are pre‑planned, not a crisis signal – investors should weigh the company’s biotech strategy and upcoming milestones before reacting.

Gyre Therapeutics’ insider filings reveal CEO Luo Ying’s 2.5M+ share options, senior exec buying, and high social buzz—indicating long‑term confidence and a potential upside ahead of hydronidone trial data.